The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
19 Jun 2024
19 Jun 2024
Historique:
received:
17
05
2024
accepted:
13
06
2024
revised:
08
06
2024
medline:
20
6
2024
pubmed:
20
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
The onset of castration-resistance is associated with dismal outcomes in patients with prostate cancer (PCa). Metastasis directed therapy has been investigated in multiple disease settings and may improve outcomes in selected patients. Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC). The literature search was performed on March 2024, on Pubmed, using the keywords "SBRT" AND "CRPC", and "stereotactic ablative radiotherapy (SABR)" AND "CRPC". This search retrieved a total of 108 articles, 19 were included. The literature is largely dominated by retrospective series. In men with metachronous oligoprogression, SBRT with androgen receptor pathway inhibitor significantly increased progression-free survival (PFS) including biochemical progression-free survival in a randomized phase II trial (hazard ratio of 0.35, p < 0.001). In patients continuing ADT, the bPFS ranged between 9.5 months to 17.9 months, and next systemic treatment-free survival (NEST-FS) reached up to 2 years. In men with induced oligoprogression, SBRT enabled NEST-FS up to 3 years. SBRT was well tolerated, with less than 5% grade 3 toxicity reported across studies. In the population of patients with oligometastatic CRPC, SBRT enables long-term biochemical response and PFS. In the oligoprogressive setting, SBRT could be integrated to prolong the duration and efficacy of systemic therapies. Nevertheless, the level of evidence remains very low and inclusion within prospective trials remain the preferred option for this population of patients.
Sections du résumé
BACKGROUND
BACKGROUND
The onset of castration-resistance is associated with dismal outcomes in patients with prostate cancer (PCa). Metastasis directed therapy has been investigated in multiple disease settings and may improve outcomes in selected patients. Our systematic review aims to summarize evidence with stereotactic body radiotherapy (SBRT) in castration-resistant prostate cancer (CRPC).
METHODS
METHODS
The literature search was performed on March 2024, on Pubmed, using the keywords "SBRT" AND "CRPC", and "stereotactic ablative radiotherapy (SABR)" AND "CRPC". This search retrieved a total of 108 articles, 19 were included.
RESULTS
RESULTS
The literature is largely dominated by retrospective series. In men with metachronous oligoprogression, SBRT with androgen receptor pathway inhibitor significantly increased progression-free survival (PFS) including biochemical progression-free survival in a randomized phase II trial (hazard ratio of 0.35, p < 0.001). In patients continuing ADT, the bPFS ranged between 9.5 months to 17.9 months, and next systemic treatment-free survival (NEST-FS) reached up to 2 years. In men with induced oligoprogression, SBRT enabled NEST-FS up to 3 years. SBRT was well tolerated, with less than 5% grade 3 toxicity reported across studies.
CONCLUSION
CONCLUSIONS
In the population of patients with oligometastatic CRPC, SBRT enables long-term biochemical response and PFS. In the oligoprogressive setting, SBRT could be integrated to prolong the duration and efficacy of systemic therapies. Nevertheless, the level of evidence remains very low and inclusion within prospective trials remain the preferred option for this population of patients.
Identifiants
pubmed: 38898265
doi: 10.1038/s41391-024-00862-8
pii: 10.1038/s41391-024-00862-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 2009;5:1403–13.
doi: 10.2217/fon.09.117
pubmed: 19903068
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79:150–8.
doi: 10.1016/j.eururo.2020.08.011
pubmed: 32907777
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197–206.
doi: 10.1056/NEJMoa2003892
pubmed: 32469184
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040–9.
doi: 10.1056/NEJMoa2001342
pubmed: 32905676
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152–60.
doi: 10.1016/S1470-2045(14)71205-7
pubmed: 25601341
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.
doi: 10.1056/NEJMoa1405095
pubmed: 24881730
pmcid: 4418931
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12.
doi: 10.1056/NEJMoa040720
pubmed: 15470213
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels J-P, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54.
doi: 10.1016/S0140-6736(10)61389-X
pubmed: 20888992
Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99.
doi: 10.1016/j.eururo.2018.03.028
pubmed: 29673712
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–28.
doi: 10.1016/S1470-2045(19)30718-1
pubmed: 31908301
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, et al. Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol. 2020;148:157–66.
doi: 10.1016/j.radonc.2020.04.003
pubmed: 32388150
Hannan R, Christensen M, Hammers H, Christie A, Paulman B, Lin D, et al. Phase II trial of stereotactic ablative radiation for oligoprogressive metastatic kidney cancer. Eur Urol Oncol. 2022;5:216–24.
doi: 10.1016/j.euo.2021.12.001
pubmed: 34986993
pmcid: 9090939
Cheung P, Patel S, North SA, Sahgal A, Chu W, Soliman H, et al. Stereotactic radiotherapy for oligoprogression in metastatic renal cell cancer patients receiving tyrosine kinase inhibitor therapy: a phase 2 prospective multicenter study. Eur Urol. 2021;80:693–700.
doi: 10.1016/j.eururo.2021.07.026
pubmed: 34399998
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): five-year results of a randomized phase II trial. J Clin Oncol. 2020;38:10.
doi: 10.1200/JCO.2020.38.6_suppl.10
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650.
doi: 10.1001/jamaoncol.2020.0147
pubmed: 32215577
pmcid: 7225913
Harrow S, Palma DA, Olson R, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET)—extended long-term outcomes. Int J Radiat Oncol Biol Phys. 2022;114:611–6.
doi: 10.1016/j.ijrobp.2022.05.004
pubmed: 35643253
Francolini G, Allegra AG, Detti B, Di Cataldo V, Caini S, Bruni A, et al. Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol. 2023;41:5561–8.
doi: 10.1200/JCO.23.00985
pubmed: 37733977
Pan J, Wei Y, Zhang T, Liu C, Hu X, Zhao J, et al. Stereotactic radiotherapy for lesions detected via 68Ga-prostate-specific membrane antigen and 18F-fluorodexyglucose positron emission tomography/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol. 2022;5:420–7.
doi: 10.1016/j.euo.2022.02.002
pubmed: 35304107
Henkenberens C, Derlin T, Bengel F, Ross TL, Kuczyk MA, Giordano FA, et al. Efficacy of PSMA PET-guided radiotherapy for oligometastatic castrate-resistant prostate cancer. Front Oncol. 2021;11:664225.
doi: 10.3389/fonc.2021.664225
pubmed: 33954116
pmcid: 8089391
Onal C, Ozyigit G, Oymak E, Guler OC, Tilki B, Hurmuz P, et al. Stereotactic radiotherapy to oligoprogressive lesions detected with 68Ga-PSMA-PET/CT in castration-resistant prostate cancer patients. Eur J Nucl Med Mol Imaging. 2021;48:3683–92.
doi: 10.1007/s00259-021-05298-z
pubmed: 33693965
Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M, et al. Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease? Eur Urol. 2019;75:548–51.
doi: 10.1016/j.eururo.2018.11.050
pubmed: 30578119
Berghen C, Joniau S, Ost P, Poels K, Everaerts W, Decaestecker K, et al. Progression-directed therapy for oligoprogression in castration-refractory prostate cancer. Eur Urol Oncol. 2021;4:305–9.
doi: 10.1016/j.euo.2019.08.012
pubmed: 31558422
Zhang H, Orme JJ, Abraha F, Stish BJ, Lowe VJ, Lucien F, et al. Phase II evaluation of stereotactic ablative radiotherapy (SABR) and immunity in 11C-Choline-PET/CT–identified oligometastatic castration-resistant prostate Cancer. Clin Cancer Res. 2021;27:6376–83.
doi: 10.1158/1078-0432.CCR-21-2510
pubmed: 34593526
pmcid: 8639778
Chamois J, Septans AL, Schipman B, Gross E, Blanchard N, Passerat V, et al. Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: a multicentric retrospective study from the French group COLib. Clin Transl Radiat Oncol. 2024;46:100762.
pubmed: 38572302
pmcid: 10987832
Tsai CJ, Yang JT, Shaverdian N, Patel J, Shepherd AF, Eng J, et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study. Lancet. 2024;403:171–82.
doi: 10.1016/S0140-6736(23)01857-3
pubmed: 38104577
Greco C, Pares O, Pimentel N, Louro V, Morales J, Nunes B, et al. Phenotype-oriented ablation of oligometastatic cancer with single dose radiation therapy. Int J Radiat Oncol Biol Phys. 2019;104:593–603.
doi: 10.1016/j.ijrobp.2019.02.033
pubmed: 30797891
Rans K, Joniau S, Berghen C, Goffin K, Dumez H, Haustermans K, et al. Progression-directed therapy in oligoprogressive castration-resistant prostate cancer: final results from the prospective, single-arm, phase 2 MEDCARE trial. Eur Urol Oncol. 2024. https://doi.org/10.1016/j.euo.2024.04.003 .
Pezzulla D, Macchia G, Cilla S, Buwenge M, Ferro M, Bonome P, et al. Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a post hoc analysis from two phase I clinical trials. Clin Exp Metastasis. 2021;38:519–26.
doi: 10.1007/s10585-021-10126-7
pubmed: 34651242
Triggiani L, Mazzola R, Magrini SM, Ingrosso G, Borghetti P, Trippa F, et al. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. World J Urol. 2019;37:2631–7.
doi: 10.1007/s00345-019-02717-7
pubmed: 30859273
La Vecchia M, Fazio I, Borsellino N, Lo Casto A, Galanti D. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide. Tumor J. 2023;109:413–7.
doi: 10.1177/03008916221132592
Ingrosso G, Detti B, Fodor A, Caini S, Borghesi S, Triggiani L, et al. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol. 2021;23:1577–84. https://doi.org/10.1007/s12094-021-02553-5 .
doi: 10.1007/s12094-021-02553-5
pubmed: 33495981
Onal C, Kose F, Ozyigit G, Aksoy S, Oymak E, Muallaoglu S, et al. Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. Prostate. 2021;81:543–52.
doi: 10.1002/pros.24132
pubmed: 33905131
Baron D, Pasquier D, Pace-Loscos T, Vandendorpe B, Schiappa R, Ortholan C, et al. Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: a multicenter retrospective analysis. Clin Transl Radiat Oncol. 2024;45:100710.
pubmed: 38179575
Franzese C, Perrino M, Marzo MA, Badalamenti M, Baldaccini D, D’Agostino G, et al. Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection. Clin Exp Metastasis. 2022;39:449–57.
doi: 10.1007/s10585-022-10158-7
pubmed: 35190933
Deek MP, Taparra K, Phillips R, Velho PI, Gao RW, Deville C, et al. Metastasis-directed therapy prolongs efficacy of systemic therapy and improves clinical outcomes in oligoprogressive castration-resistant prostate cancer. Eur Urol Oncol. 2021;4:447–55.
doi: 10.1016/j.euo.2020.05.004
pubmed: 32536574
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091–102.
doi: 10.1056/NEJMoa1911440
pubmed: 32343890
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–103.
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5:471–8.
doi: 10.1001/jamaoncol.2018.5801
pubmed: 30589920
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366. https://doi.org/10.1056/NEJMoa1200690 .
Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–7.
doi: 10.1200/JCO.2016.69.1584
pubmed: 28034081
Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:700–12.
doi: 10.1016/S1470-2045(14)70189-5
pubmed: 24831977
pmcid: 4418935
Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, et al. Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial. Eur Urol. 2022;81:253–62.
doi: 10.1016/j.eururo.2021.08.011
pubmed: 34493414
Fakhrejahani F, Madan RA, Dahut WL, Karzai F, Cordes LM, Schlom J, et al. Avelumab in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35:159.
doi: 10.1200/JCO.2017.35.6_suppl.159
Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Mathews D, et al. Phase II trial of sipuleucel-T and stereotactic ablative body radiation for patients with metastatic castrate-resistant prostate cancer. Biomedicines. 2022;10:1419.
doi: 10.3390/biomedicines10061419
pubmed: 35740441
pmcid: 9220346
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–22.
doi: 10.1056/NEJMoa1001294
pubmed: 20818862
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82.
doi: 10.1016/j.eururo.2020.09.046
pubmed: 33039206
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25.
doi: 10.1200/JCO.2005.01.529
pubmed: 15860850
James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with newly diagnosed metastatic prostate cancer in the ‘Docetaxel Era’: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67:1028–38.
doi: 10.1016/j.eururo.2014.09.032
pubmed: 25301760
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.
doi: 10.1200/JCO.2015.64.2702
pubmed: 26903579
pmcid: 4872347
D’Angelillo RM, Francolini G, Ingrosso G, Ravo V, Triggiani L, Magli A, et al. Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: a position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). Crit Rev Oncol Hematol. 2019;138:24–8.
doi: 10.1016/j.critrevonc.2019.03.014
pubmed: 31092381
Zilli T, Achard V, Dal Pra A, Schmidt-Hegemann N, Jereczek-Fossa BA, Lancia A, et al. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199–207.
doi: 10.1016/j.radonc.2022.10.005
pubmed: 36228761
Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, et al. The impact of
doi: 10.2967/jnumed.117.197160
pubmed: 28646014
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, et al. Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res. 2019;25:7448–54.
doi: 10.1158/1078-0432.CCR-19-1050
pubmed: 31511295
Chen W, Li L, Ji S, Song X, Lu W, Zhou T. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis. Eur J Clin Pharm. 2019;75:1521–32.
doi: 10.1007/s00228-019-02736-8